Search Results - "Meiser, Karin"

Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses by Gauvreau, Gail M., PhD, Arm, Jonathan P., MD, Boulet, Louis-Philippe, MD, Leigh, Richard, MBChB, Cockcroft, Donald W., MD, Davis, Beth E., PhD, Mayers, Irvin, MD, FitzGerald, J. Mark, MB, Dahlen, Barbro, MD, Killian, Kieran J., MB, Laviolette, Michel, MD, Carlsten, Christopher, MD, Lazarinis, Nikolaos, MD, Watson, Richard M., BSc, Milot, Joanne, BSc, Swystun, Veronica, PhD, Bowen, Miranda, MSc, Hui, Linda, MSc, Lantz, Ann-Sofie, MSc, Meiser, Karin, PhD, Maahs, Suzanne, PharmD, Lowe, Philip J., PhD, Skerjanec, Andrej, PhD, Drollmann, Anton, MD, O'Byrne, Paul M., MB

“…Background Omalizumab is an established anti-IgE therapy for the treatment of allergic diseases that prevents IgE from binding to its receptor. QGE031 is an…”
Get full text

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study by Mease, Philip, van der Heijde, Désirée, Landewé, Robert, Mpofu, Shephard, Rahman, Proton, Tahir, Hasan, Singhal, Atul, Boettcher, Elke, Navarra, Sandra, Meiser, Karin, Readie, Aimee, Pricop, Luminita, Abrams, Ken

“…To evaluate the effect of subcutaneous (s.c.) secukinumab, an interleukin-17A inhibitor, on clinical signs and symptoms and radiographic progression in…”
Get more information

A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia by Rees, David C., Kilinc, Yurdanur, Unal, Selma, Dampier, Carlton, Pace, Betty S., Kaya, Banu, Trompeter, Sara, Odame, Isaac, Mahlangu, Johnny, Unal, Sule, Brent, Julie, Grosse, Regine, Fuh, Beng R., Inusa, Baba P.D., Koren, Ariel, Leblebisatan, Goksel, Levin, Carina, McNamara, Elizabeth, Meiser, Karin, Hom, Douglas, Oliver, Stephen J.

“…Excessive intravascular release of lysed cellular contents from damaged red blood cells (RBCs) in patients with sickle cell anemia (SCA) can activate the…”
Get full text

Pharmacodynamic Effects of Steady-State Fingolimod on Antibody Response in Healthy Volunteers: A 4-Week, Randomized, Placebo-Controlled, Parallel-Group, Multiple-Dose Study by Boulton, Craig, Meiser, Karin, David, Olivier J., Schmouder, Robert

“…Fingolimod, a first-in-class oral sphingosine 1-phosphate receptor (S1PR) modulator, is approved in many countries for relapsing-remitting multiple sclerosis,…”
Get full text

Effect of fingolimod (FTY720) on cerebral blood flow, platelet function and macular thickness in healthy volunteers by Ocwieja, Magdalena, Meiser, Karin, David, Olivier J., Valencia, Jessica, Wagner, Frank, Schreiber, Stephan J., Pleyer, Uwe, Ziemer, Sabine, Schmouder, Robert

“…Aim Fingolimod, a sphingosine 1‐phosphate receptor modulator, is the first oral disease modifying therapy approved for the treatment of relapsing multiple…”
Get full text

Comparing QT interval variability of semiautomated and high‐precision ECG methodologies in seven thorough QT studies—implications for the power of studies intended for definitive evaluation of a drug's QT effect by Meiser, Karin, Jordaan, Pierre, Latypova, Sasha, Darpo, Borje

“…Background In studies of drug effects on electrocardiographic parameters, the level of precision in measuring QTc interval changes will influence a study's…”
Get full text

Pharmacokinetics of fingolimod and metabolites in subjects with severe renal impairment: An open-label, single-dose, parallel-group study by David, Olivier J, Pryce, Maxwell, Meiser, Karin, Picard, Franck, Emotte, Corinne, Kobalava, Zhanna, Moiseev, Valentin, Schmouder, Robert

“…This study assessed the pharmacokinetics and tolerability of fingolimod and its metabolites in severe renal impairment and healthy subjects. In this…”
Get full text

Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results by David, Olivier J, Ocwieja, Magdalena, Meiser, Karin, Emotte, Corinne, Jakab, Annamaria, Wemer, Johan, den Daas, Izaak, Schmouder, Robert

“…Fingolimod has a novel mechanism of action in multiple sclerosis, being a first-in-class sphingosine 1-phosphate receptor modulator. Because of a potential…”
Get full text

Pharmacokinetics of single and multiple oral doses of valsartan/amlodipine (80/5 mg) in healthy Chinese subjects by Duan, Jingli, Chen, Jin, Yin, Qi, Karan, Rajesh, Meiser, Karin, Smith, Harold Tom, Sunkara, Gangadhar

“…The efficacy and safety of valsartan/amlodipine combination have been demonstrated for the treatment of hypertension. In China, where the prevalence of…”
Get full text

Sotrastaurin single-dose pharmacokinetics in de novo liver transplant recipients by Kovarik, John M, Neuhaus, Peter, Cillo, Umberto, Weber, Markus, Stitah, Sylvie, Gatlik, Ewa, Meiser, Karin, Slade, Alan

“…Sotrastaurin is a protein kinase C inhibitor in development for prevention of rejection after liver transplantation. In a pharmacokinetic study, 13 de novo…”
Get more information

Tolerability and Pulmonary Pharmacodynamic Effects During Treatment Initiation of Once-Daily Oral Fingolimod in Subjects With Moderate Asthma by Boulton, Craig, David, Olivier J., Meiser, Karin, Schmouder, Robert

“…Fingolimod, a first‐in‐class sphingosine 1‐phosphate receptor modulator, is the first approved oral therapy for relapsing multiple sclerosis (MS). While…”
Get full text

Pharmacodynamic Effects of Steady-State Fingolimod on Antibody Response in Healthy Volunteers: A 4-Week, Randomized, Placebo-Controlled, Parallel-Group, Multiple-Dose Study by Boulton, Craig, Meiser, Karin, David, Olivier J, Schmouder, Robert

Get full text